Also known as CKD-602 and Camtobell.
Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.
TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.